Holen Sie sich die Stockscreener-App
0.3097
1.49%
-0.0047
Handel nachbörslich:
.31
0.0003
+0.10%
Schlusskurs vom Vortag:
$0.3144
Offen:
$0.3123
24-Stunden-Volumen:
328.08K
Relative Volume:
0.17
Marktkapitalisierung:
$28.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.23M
KGV:
-0.7244
EPS:
-0.4275
Netto-Cashflow:
$-34.82M
1W Leistung:
-10.41%
1M Leistung:
-14.61%
6M Leistung:
-88.61%
1J Leistung:
-69.02%
1-Tages-Spanne:
$0.3032
$0.317
1-Wochen-Bereich:
$0.2965
$0.3493
52-Wochen-Spanne:
$0.2965
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.3097 | 31.76M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Context Therapeutics Inc (CNTX-Q) Stock Price and News - The Globe and Mail
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
Context Therapeutics (NASDAQ:CNTX) Share Price | RNS News, Quotes, & Charts | CNTX | - Proactive financial news
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Live Context Therapeutics Inc. (CNTX) Technical Analysis - Traders Union
CNTX Stock Price, Quote & Chart - ChartMill
CNTX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesEstimate Revision Count - dars.gov.et
Knight Therapeutics: Business Profile and TSX Market Context - Kalkine Media
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in Nectin-4-Positive Tumors - GenomeWeb
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 - marketscreener.com
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid Tumors - Quiver Quantitative
A cancer treatment enters human testing for three cancers - Stock Titan
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 - Yahoo Finance
Can Context Therapeutics (NASDAQ:CNTX) Afford To Invest In Growth? - simplywall.st
Context Therapeutics (CNTX) Edges Up 1.56% as Stock Holds Above $0.37 SupportRisk Reward Setups - vinanet.vn
Context (CNTX) Q2 2026 Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Stock Move: The Market Price Declines 3.77% in the Latest SessionEstimate Revision Count - vinanet.vn
Context Therapeutics Inc. Revenue Breakdown – NASDAQ:CNTX - TradingView
Context (CNTX) Q2 2026 Results: The Available Earnings Metric Delivers a Miss for This Review; Post-Report: Shares Finish 2.19% Up on the DayNext Quarter Guidance - vinanet.vn
Context (CNTX) Quarterly Figures: EPS Comes in Below Forecast for This Review; Post-Earnings: Shares Fall 1.81% - vinanet.vn
Enterprise value to EBITDA forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
a2026mar-contextxcorpdec.htm - SEC.gov
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Context Therapeutics Inc. (CNTX) Stock Price, News, Quote & History - Yahoo Finance
CNTX Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Climb 7.77%Revenue Growth Outlook - dars.gov.et
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Context Therapeutics (CNTX) Slips 6.6% to $0.45, Pressing Key Support at $0.43Factor Rotation - dars.gov.et
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
LifeSci Capital Maintains Context Therapeutics(CNTX.US) With Hold Rating, Announces Target Price $2 - Moomoo
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context drops bispecific T-cell engager on cost-cutting initiative - Yahoo Finance
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - marketbeat.com
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
CNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingView
Context Therapeutics (CNTX) Advances 2.93% as Biotech Tests Key $0.65 Resistance ZoneMonthly Profile - vinanet.vn
Weekly Recap: CNTX Nasdaq notice and Q2 2026 $0.09 loss forecast - TradingView
Enterprise value to revenue forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):